Articles tagged "Immunosuppression"

2019 American Transplant Congress
Prevalence of Varicella Zoster Infection in Renal Transplant Recipients
P. T. Gaynor, D. Nanayakkara, O. E. Beaird, J. Schaenman, S. Bunnapradist
Infectious Diseases, UCLA, Los Angeles, CA
*Purpose: Varicella zoster infection is a serious complication of immunosuppression in renal transplant recipients. We examined the prevalence of VZV infection in renal transplant patients…
2019 American Transplant Congress
Combination of Ketoconazole and Tacrolimus Increases the Risk of Kidney Transplant Rejection in African Americans
M. E. Sharshir, A. Zhang, E. Khan, B. Zhang, S. Giusti, R. Zhang
Nephrology, Tulane University, New Orleans, LA
*Purpose: African American patients generally have a rapid metabolism and thus require higher doses of tacrolimus after kidney transplantation. Ketoconazole inhibits tacrolimus metabolism and can…
2019 American Transplant Congress
Use of Eculizumab for Active Antibody-Mediated Rejection That Occurs Early Post-Kidney Transplantation: A Consecutive Series of 15 Cases
E. Tan¹, B. J. Andrew², P. G. Dean², M. F. Shaheen¹, M. D. Stegall², C. A. Schinstock²
¹Division of Transplantation Surgery, Mayo Clinic Rochester, Rochester, MN, ²The William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic Rochester, Rochester, MN
*Purpose: Active antibody-mediated rejection (ABMR) that occurs during the amnestic response within the first month post-transplant is a rare but devastating cause of early allograft…
2019 American Transplant Congress
Transplant Regimen Adherence For Kidney Recipients By Engaging Information Technologies: The Take It Trial
D. P. Ladner¹, M. S. Wolf²
¹Surgery, Northwestern Medicine, Chicago, IL, ²General Internal Medicine, Northwestern University, Chicago, IL
*Purpose: Several studies report a high prevalence of inadequate adherence to prescribed (Rx) immunosuppressive (IS) medication regimens among kidney transplant (KT) recipients, yet few interventions…
2019 American Transplant Congress
Patient-Reported Outcomes in a Prospective Multicenter Trial of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression Regimens in Kidney Transplantation
J. M. Rohan¹, J. P. Leone², E. S. Woodle³, D. Kaufman⁴, A. R. Shields³, A. Wiseman⁵, A. J. Matas⁶, P. West-Thielke⁷, E. King³, R. R. Alloway³
¹Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, VA, ²Tampa General Hospital, Tampa, FL, ³University of Cincinnati College of Medicine, Cincinnati, OH, ⁴University of Wisconsin – Madison, Madison, WI, ⁵University of Colorado - Denver, Denver, CO, ⁶University of Minnesota Medical Center, Minneapolis, MN, ⁷University of Illinois – Chicago, Chicago, IL
*Purpose: Previous trials have not examined differences in patient-reported outcomes (PRO) between belatacept (BELA)- and tacrolimus (TAC)-based therapies in adult kidney transplant (KTx) patients (pts).…
2019 American Transplant Congress
Tacrolimus Pharmacokinetics in Young, Middle Age and Older Renal Transplant Recipients- Impact of CYP3A5*3*6*7 Metabolic Composite
K. Tornatore¹, K. Attwood², D. Brazeau³, R. Venuto⁴
¹University at Buffalo; School of Pharmacy, Buffalo, NY, ²Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, ³Marshall University; School of Medicine, Huntington, WV, ⁴University at Buffalo; School of Medicine, Buffalo, NY
*Purpose: In spite of increased renal transplantation in patients over 60 years and the need for age-adjusted tacrolimus maintenance immunosuppression, limited pharmacokinetic comparisons between young,…
2019 American Transplant Congress
Selective CD28 Blockade-Mediated Inhibition of T Follicular Helper Cell and DSA Responses is CTLA-4 Dependent
G. M. La Muraglia II, M. L. Ford, I. R. Badell
Emory Transplant Center, Atlanta, GA
*Purpose: Clinical costimulation blockade of the CD28 pathway in the form of CTLA-4Ig has shown the ability to attenuate T cell dependent DSA responses. However,…
2019 American Transplant Congress
Impact of Induction Choice and Early Steroid Withdrawal on Outcomes in HLA Zero Mismatched Kidney Transplant Recipients
C. Votruba¹, K. Holdener¹, B. Astor², F. Aziz², D. Mandelbrot²
¹Pharmacy, University of Wisconsin Hospitals and Clinics, Madison, WI, ²Nephrology, University of Wisconsin Hospitals and Clinics, Madison, WI
*Purpose: Ideal induction and immunosuppression therapy for 6-antigen HLA matched deceased and living kidney transplant recipients (KTR) is not well understood.*Methods: All 6-antigen HLA matched…
2019 American Transplant Congress
Belatacept Conversion for Calcineurin Inhibitor-Associated Thrombotic Microangiopathy in Kidney Transplant Recipients
S. A. Muhsin, K. Safa, H. M. Gilligan, E. C. Heher, W. W. Williams, D. M. Wojciechowski
Nephrology Division, MGH, Boston, MA
*Purpose: Thrombotic Microangiopathy (TMA) in kidney transplant recipients is a serious complication that can cause graft loss. It can be associated with immunosuppressive medications such…
2019 American Transplant Congress
Immunobiogram, a New IVD Immunoassay to Test the Sensitivity Profile of Kidney Transplant Recipients to Immunosuppressive Drugs: Further Results from BH-Pilot Study
C. Jimenez¹, J. M. Portoles², D. Blánquez³, L. Arribas³, A. Ortega⁴, T. Diez⁵, I. Portero⁶
¹Nephrology Department, La Paz Hospital, Madrid, Spain, ²Nephrology Department, Puerta de Hierro Mahadahonda Hospital, Madrid, Spain, ³Adamas Engineering Consulting, Madrid, Spain, ⁴I+D, Biohope, Madrid, Spain, ⁵Medical, Biohope, Madrid, Spain, ⁶CEO, Biohope, Madrid, Spain
*Purpose: IMBG is an immunoassay developed by Biohope to measure in vitro PBMC sensitivity/resistance profile to a panel of immunosuppressive drugs (IS) in Kidney Transplant…